Nektar Therapeutics (NKTR) Tops Q3 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Nektar Therapeutics (NKTR) PT Raised to $20 at Oppenheimer
November 7, 2019 10:24 AM ESTOppenheimer analyst Jay Olson raised the price target on Nektar Therapeutics (NASDAQ: NKTR) to $20.00 (from $18.00) while maintaining a Perform rating.
The analyst commented, "Nektar reported 3Q19 financial results, revised 2019 guidance, and provided pipeline updates including multiple catalysts. While NKTR has several promising... More
